We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Once a week, Sun Kai has a video call with his mother, and they discuss his day-to-day life. But Sun’s mother died five years ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Researchers use CRISPR to overcome seemingly insurmontable reproductive barriers — but that doesn't mean this could work for ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.